Vertex Pharmaceuticals Misses Wall Street Estimates for Quarterly Results
Bengaluru, May 6, 2025 – Vertex Pharmaceuticals, the leading pharmaceutical company, missed Wall Street estimates for its quarterly results on Monday due to lower-than-expected sales of its cystic fibrosis (CF) drug Trikafta. Despite this setback, the company raised the lower end of its revenue forecast, focusing on its acute pain drug Journavx and newer CF drugs to drive growth beyond its established line of treatments.
In December, the U.S. Food and Drug Administration approved Vertex’s next-generation treatment, Alyftrek, which further strengthens the company’s market dominance in CF treatments. The company has activated more than 65 authorized treatment centers globally and 90 patients have begun cell collection for its gene therapy Casgevy, which treats a rare blood disorder requiring regular blood transfusions.
Vertex’s total quarterly revenue rose 2.7% to $2.77 billion, missing analysts’ estimates of $2.85 billion. On an adjusted basis, the company reported a profit of $4.06 per share for the quarter, compared to analysts’ expectations of $4.32.
Join the Community of 2M+ Industry Professionals
Subscribe to our newsletter to get the latest insights and analysis.
